Acetium
PreclinicalSmall molecule
Acetium is one of 49 small molecule programs targeting Headache. It is currently in Preclinical.
3
Indications
3
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
154 competitors in Smoking Cessation
#DrugCompanyPhaseTrials
1Wellbutrin
GSKPhase 3
Chantix
PfizerPhase 3
Ozempic
Novo NordiskPhase 3
Topamax
WWim Janssens
Phase 3
Rimonabant
SanofiPhase 3
Pharmacotherapy
UUniversity of Pittsburgh
Phase 3
Standard Treatment
Boehringer IngelheimPhase 3
EMB-01
SShanghai EpimAb Biotherapeutics Co., Ltd.
Phase 3
Nicotine Pod
YYale University
Phase 3
Nicotine Gum
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Acetium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBiohit Oyj